A Phase 2a, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Intravenously Administered Nerofe in Subjects With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Trial Profile

A Phase 2a, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Intravenously Administered Nerofe in Subjects With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Tumour cells apoptosis factor (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Immune System Key
  • Most Recent Events

    • 02 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top